Adaptive Biotechnologies Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 48.93 million compared to USD 43.66 million a year ago. Net loss was USD 47.81 million compared to USD 52.05 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.37 a year ago. Diluted loss per share from continuing operations was USD 0.33 compared to USD 0.37 a year ago.
For the six months, sales was USD 86.57 million compared to USD 82.28 million a year ago. Net loss was USD 105.51 million compared to USD 114.78 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.81 a year ago. Diluted loss per share from continuing operations was USD 0.73 compared to USD 0.81 a year ago.